A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Cannabis Bioscience International Holdings, Inc.
CBIH
$2M
Mkt Cap
$0.00
+100.00%
Cannabis Bioscience International Holdings, Inc. (CBIH) has a market capitalization of $2M. It is classified as a small-cap stock.
Cannabis Bioscience International Holdings, Inc. (CBIH) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.29%.
Cannabis Bioscience International Holdings, Inc. (CBIH) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
Cannabis Bioscience International Holdings, Inc. (CBIH) reported annual revenue of $303 thousand in its most recent fiscal year, based on SEC EDGAR filings.
Cannabis Bioscience International Holdings, Inc. (CBIH) has a net profit margin of -181.1%. The company is currently unprofitable.
Cannabis Bioscience International Holdings, Inc. (CBIH) generated $-330 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
The Company was formed in Colorado on February 28, 2003, as a limited liability company under the name Fidelity Aircraft Partners LLC. On December 16, 2009, it converted to a corporation under the name Fidelity Aviation Corporation, and on August 24, 2004, it changed its name to China Infrastructure Construction Corp. On February 28, 2018, the Company changed its name to Hippocrates Direct Healthcare, Inc., and on December 6, 2022, it changed its corporate name to Cannabis Bioscience International Holdings, Inc. The Company’s vision is to provide superior services while adhering to its core values of integrity, respect, compassion, inclusiveness, social responsibility, excellence and innovation. The Company has three businesses: ·The Company conducts a business generally related to cannabis-related research and education under the trade name Pharmacology University (the “Pharmacology University Business”).
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 124K | 303K | - | - |
| Net Income | -515K | -549K | -651K | -1.0M |
| EPS | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Free Cash Flow | 0 | -330K | -479K | -898K |
| ROIC | -20405.9% | -1044.2% | -671.9% | -1790.7% |
| Gross Margin | 78.8% | 86.8% | - | - |
| Debt/Equity | 0.00 | -0.23 | -0.24 | -0.45 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -399K | -421K | -486K | -983K |
| Operating Margin | -322.6% | -139.1% | - | - |
| ROE | 0.0% | 48.9% | 78.0% | 216.8% |
| Shares Outstanding | 11,627M | 10,976M | 10,856M | 9,387M |
| Metric | ||||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | 303K | 124K |
| Gross Margin | N/A | N/A | 86.8% | 78.8% |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | 177K | 124K | 102K | 31K |
| EBIT | -983K | -486K | -421K | -399K |
| Op. Margin | N/A | N/A | -139.1% | -322.6% |
| Net Income | -1.0M | -651K | -549K | -515K |
| Net Margin | N/A | N/A | -181.1% | -416.8% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | N/M | N/M | N/M | N/M |
| ROE | 216.8% | 78.0% | 48.9% | 0.0% |
| ROA | -2380.2% | -1295.6% | -1232.7% | -33373.7% |
| Cash Flow | ||||
| Op. Cash Flow | -898K | -479K | -330K | -268K |
| Free Cash Flow | -898K | -479K | -330K | 0 |
| Owner Earnings | -910K | -479K | -330K | -268K |
| CapEx | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 30K | 30K |
| Buyback Yield | N/A | N/A | N/A | 1.3% |
| Stock-Based Comp | 12K | 0 | N/A | N/A |
| Debt Repayment | 0 | 30K | 24K | 24K |
| Balance Sheet | ||||
| Net Debt | 255K | 256K | 251K | 376K |
| Cash & Equiv. | 9K | 0 | 13K | 0 |
| Long-Term Debt | 250K | 249K | 250K | 250K |
| Debt/Equity | -0.45 | -0.24 | -0.23 | 0.00 |
| Interest Coverage | -10.8 | -3.2 | -3.1 | -3.1 |
| Equity | -592K | -1.1M | -1.2M | -1.5M |
| Total Assets | 43K | 57K | 32K | 2K |
| Total Liabilities | 635K | 1.1M | 1.2M | 1.5M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -4.7M | -5.3M | -5.9M | -6.2M |
| Working Capital | -366K | -860K | -917K | -1.2M |
| Current Assets | 19K | 21K | 29K | 2K |
| Current Liabilities | 386K | 882K | 946K | 1.2M |
| Per Share Data | ||||
| EPS | -0.00 | -0.00 | -0.00 | -0.00 |
| Owner EPS | -0.00 | -0.00 | -0.00 | -0.00 |
| Book Value | -0.00 | -0.00 | -0.00 | -0.00 |
| Cash Flow/Share | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 9.4B | 10.9B | 11.0B | 11.6B |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -4.3 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 25.9 | 18.8 |
| FCF Yield | N/A | -8.0% | -5.0% | N/A |
| Market Cap | N/A | 6.0M | 6.6M | 2.3M |
| Avg. Price | N/A | 0.00 | 0.00 | 0.00 |
| Year-End Price | N/A | 0.00 | 0.00 | 0.00 |
Cannabis Bioscience International Holdings, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 86.8%. Total shareholder yield (buybacks) is 1.3%.
Cannabis Bioscience International Holdings, Inc. (CBIH) reported earnings per share (EPS) of $-0.00 in its most recent fiscal year.
Cannabis Bioscience International Holdings, Inc. (CBIH) has a return on equity (ROE) of 48.9%. This indicates the company generates strong returns for shareholders.
Cannabis Bioscience International Holdings, Inc. (CBIH) has a 5-year average gross margin of 86.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 3 years of financial data for Cannabis Bioscience International Holdings, Inc. (CBIH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cannabis Bioscience International Holdings, Inc. (CBIH) has a book value per share of $-0.00, based on its most recent annual SEC filing.